Altria Abandons Option to Buy Additional Cronos Shares.

Dec.20.2022
Altria Abandons Option to Buy Additional Cronos Shares.
Altria Group cancels option to buy additional shares in Cronos Group, resulting in a $483 million capital loss.

According to a press release from Altria, the company has notified Cronos Group that it has irrevocably relinquished its options to purchase additional common shares of Cronos, as well as any ownership rights or common shares underlying those options, without any consideration.


In March 2019, Altria, through its subsidiary, acquired a 45% stake and stock warrants in Cronos. The warrants can be exercised before March 8, 2023, at a price of CAD 19 (USD 13.93) per share. Prior to abandoning the warrants, Altria's subsidiary held 156,573,537 common shares of Cronos (approximately 41% of the issued and outstanding common shares), and through full exercise of the warrants, could increase its ownership to 240,816,760 common shares of Cronos (approximately 52% of the issued and outstanding common shares after full exercise of the warrants).


On December 15th, 2022, the closing price for Cronos common shares was $3.81 CAD ($2.79 USD), and for the past 12 months, the trading price for Cronos common shares has not exceeded $6 CAD ($4.39 USD). Considering Cronos' trading level and the expiration of its warrants in March 2023, on December 16th, 2022, Altria decided to forfeit its warrants. As a result of forfeiting the warrants, Altria expects to claim a capital loss of $483 million USD in its 2022 federal merger asset tax return. Altria will continue to hold 156,573,537 shares of Cronos common stock.


Tobacco company Altria holds common stock in Cronos through its subsidiary for investment purposes. Altria will continue to assess Cronos' business and prospects, as well as all other relevant factors, to determine whether it or its affiliates will dispose of such shares on the open market through private negotiation transactions (possibly involving Cronos or third parties) or through other means.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
Ahead of World No Tobacco Day 2026, WHO released its first global report on nicotine pouches, warning that rapid market growth, youth-oriented marketing and weak regulation are converging. 2Firsts views the report as an important warning, but not a complete risk assessment, with harm-reduction questions still unresolved.
Special Report
May.17
ITC Keeps Exclusion and Cease-and-Desist Orders in Place Against Stiiizy
ITC Keeps Exclusion and Cease-and-Desist Orders in Place Against Stiiizy
U.S. International Trade Commission has refused to pause the import and sales bans imposed on cannabis vape company Stiiizy while it appeals the agency’s patent infringement ruling in its dispute with Pax Labs.
Apr.07 by 2FIRSTS.ai
FDA and NIH Release New Wave 8 Restricted-Use PATH Study Data Files
FDA and NIH Release New Wave 8 Restricted-Use PATH Study Data Files
FDA’s Center for Tobacco Products and NIH’s National Institute on Drug Abuse announced that new Wave 8 restricted-use data files from the PATH Study are now available. The files contain data collected between January 2024 and December 2024, including questionnaire data, location characteristics data, and state identifier data.
Apr.17 by 2FIRSTS.ai
Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million
Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million
Ispire Technology reported financial results on May 7, 2026, for the third quarter of fiscal 2026, covering the three months ended March 31, 2026. Revenue was $18.7 million, compared with $26.2 million in the third quarter of fiscal 2025 and $20.3 million in the prior quarter. Gross profit was $2.0 million, with gross margin of 10.7%. Net loss was $9.5 million, or $0.17 per share. The company said it held $18.0 million in cash as of March 31, 2026, up $468,000 sequentially.
May.08 by 2FIRSTS.ai
 China’s E-Cigarette Exports Reached About USD 903 Million in March 2026, Up 4.4% Year on Year
China’s E-Cigarette Exports Reached About USD 903 Million in March 2026, Up 4.4% Year on Year
According to the latest country-level data released by China’s General Administration of Customs, China’s e-cigarette-related exports totaled about USD 903 million in March 2026, up about 4.4% from roughly USD 865 million a year earlier. The United States, the United Kingdom and Germany remained the top three destinations, while the top 10 markets together accounted for about 72.2% of total exports.
Apr.21 by 2FIRSTS.ai
Why Many E-Liquids Today Are "Not Bad, but Not Memorable" – Mylor’s Approach to Experience Design
Why Many E-Liquids Today Are "Not Bad, but Not Memorable" – Mylor’s Approach to Experience Design
From May 8 to 10, 2026, Mylor (Booth E70) will exhibit at The Vaper Expo UK, where it will showcase its systematic experience design solutions for e-liquids. At present, the e-liquid market commonly faces a challenge: many products have “no obvious shortcomings, but lack memorable features.” In response, Mylor has proposed refined solutions across multiple dimensions, including device-adaptive sweetness, progressive cooling sensation, fruit-oriented sourness, and segmented nicotine experience.
May.08